Takeda strengthens cancer focus with Mersana ADC deal | PharmaBoardroom
written on 08.04.2014
Tags:
,

Takeda strengthens cancer focus with Mersana ADC deal

TAGS: ,

Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.

Latest Report